



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>CORRECTED SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/783,268
				Filing Date	February 20, 2004
				First Named Inventor	Andrea Savarino
				An Unit	1617
				Examiner Name	Wang, Shengjun
Sheet	2	of	2	Attorney Docket Number	97728.00147

RECEIVED  
CENTRAL FAX CENTER

DEC 06 2006

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.	T <sup>2</sup>
/JSI/	1.	Treatment for HIV related inflammation, Treatment Review, May 1995 (no. 18) Abstract	
/JSI/	2.	Hydroxychloroquine+ddl+hydroxyurea antiretroviral trial, AIDS Research Alliance, Los Angeles, AIDS Treatment News, December 3, 1990 (No. 332)	
/JSI/	3.	BOELAET, et al. The Additive I Vitro and Anti-HIV-1 Effect of Chloroquine When Combined with Zidovudine and Hydroxyurea, Biochemical Pharmacology 2001, Vol. 61, pages 1531-1535.	
/JSI/	4.	CHUKWUEMEKA, A Management of HIV-Infected Pregnant Patients in Malaria-Endemic Areas; Therapeutic and Safety Considerations in ConComitant Use of Antiviral and Antimalarial Agents, Clinic Therapeutics, 1999, Vol. 21, No. 9, 1999, pages 1456-1496	
		/Jagadishwar Samala/ (08/14/2007)	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application for to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ME16013122.1